Physician profile
Mark S Mabus
NPI 1407010630
$6,271.92
in general payments reported to CMS, 2019-2025
14 companies · $1,585 in 2025
The $1,585 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2021: $42.57 · 2022: $228 · 2023: $168 · 2024: $3,999 · 2025: $1,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,800 · Consulting Fee: $1,520 · Food and Beverage: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,800.00 |
| Consulting Fee | $1,520.00 |
| Food and Beverage | $431.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,389.01 | 2019-2025 | |
| Abbvie INC. | $175.80 | 2022-2025 | |
| Novo Nordisk INC | $118.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $110.09 | 2019-2024 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.61 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $83.41 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $67.80 | 2022 | |
| Merck Sharp & Dohme LLC | $65.08 | 2021-2022 | |
| Amgen INC. | $49.10 | 2019-2022 | |
| Exact Sciences Corporation | $32.72 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $27.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.45 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.79 | 2022 | |
| Bausch Health US, LLC | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mabus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.